Hemab Therapeutics Holdings, Inc. Common Stock

NASDAQ:COAG

Biotechnology

Healthcare
$39.15 +8.79%

+$2.32 today

Market cap
$1.83B
Beta
0.00
52W Low $23.00High $36.61

Volume 0.30M

Average 0.34M

COAG Net Income

Bottom-line profit after all expenses, interest, and taxes.

Hemab Therapeutics Holdings, Inc. Common StockNASDAQ: COAG

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income of -$24.15M in Q2 FY2026

Q2 FY2026 net income was -$24.15M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$24.15M-6.4% QoQ
Last fiscal yearDec 2025
-$63.91M— YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Income history

USD · from the income statement

Latest · FY2025
(63.91M) USD
Year-over-year change
—

Net Income vs competitors

How COAG compares with its peers on the latest reported figures

  • COAG's FY2025 net income of -$63.91M is the 2nd highest of the 5 companies compared; the peer median is -$221.98M.
COAG Competitors Peer median
Net Income for COAG and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RLYBRallybio CorporationLTM Mar 2026-$7.82M +83.8%—911.1%
COAGHemab Therapeutics Holdings, Inc. Common StockFY2025-$63.91M ———
QUREuniQure N.V.LTM Mar 2026-$208.87M +4.0%—1154.4%
DMRADamora Therapeutics, Inc.LTM Mar 2026-$235.09M -1171.1%——
IRONDisc Medicine, Inc.LTM Sep 2026-$243.1M -34.2%——
Peer median (excluding COAG) -$221.98M-15.1%—1032.7%

Competitors are the stored peer set for COAG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Hemab Therapeutics Holdings, Inc. Common Stock

NASDAQ:COAG

Intrinsic Alpha fair value

Locked

Current Price

$39.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.